Shopping Cart
- Remove All
- Your shopping cart is currently empty
Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $31 | In Stock | |
50 mg | $42 | In Stock | |
100 mg | $79 | In Stock | |
200 mg | $117 | In Stock | |
500 mg | $193 | In Stock | |
2 g | $419 | In Stock | |
1 mL x 10 mM (in DMSO) | $46 | In Stock |
Description | Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity. |
In vitro | METHODS: Human eosinophil EoL-1 cells were treated with Bucladesine sodium (10-100 µM) for 8 days and activity was measured using PKA assay. RESULTS: Proliferation of EoL-1 cells treated with Bucladesine sodium increased in a time-dependent manner. [1] METHODS: PC12 cells were treated with Bucladesine sodium (1 mM) for 72 h. TNF-α levels were measured by ELISA assay. RESULTS: Bucladesine sodium increased the activity of PKA. [2] |
In vivo | METHODS: To study the anti-inflammatory activity in vivo, Bucladesine sodium (0.24-0.7 µg/kg) was administered intraperitoneally to a mouse model of copper pine demyelination once daily for seven days. RESULTS: Bucladesine had a protective effect on myelin formation. Enhanced intracellular cAMP prevented demyelination and exerted anti-inflammatory and anti-apoptotic properties in a mouse model of copper pine demyelination. [3] METHODS: To investigate the effects on liver injury, Bucladesine sodium (0.5-500 mg/kg) was intraperitoneally injected into C57BL/6J jcl mice, and liver injury was induced by the intravenous injection of rTNF-α (1.0 µg/kg) and intraperitoneal injection of D-gal (500 mg/kg) after 1 h. The RESULTS showed that Bucladesine protected against hepatic injury in C57BL/6J jcl mice. RESULTS: Bucladesine protected mice from TNF-α/D-gal-induced liver injury.Bucladesine significantly enhanced the expression of Hsp70 in hepatocytes of D-gal/TNFα-injected mice, which was closely related to the inhibition of liver injury. [4] |
Animal Research | Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p. |
Alias | Sodium dibutyryl cAMP, Dibutyryl-cAMP sodium salt, Dibutyryl-cAMP, DC2797, dbcAMP, Bucladesine sodium salt, Bucladesine |
Molecular Weight | 491.37 |
Formula | C18H23N5NaO8P |
Cas No. | 16980-89-5 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: 49.1 mg/mL (100 mM) DMSO: 55 mg/mL (111.93 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.